首页|散寒化湿颗粒对人冠状病毒229E和OC43感染致小鼠肺炎的作用机制研究

散寒化湿颗粒对人冠状病毒229E和OC43感染致小鼠肺炎的作用机制研究

The mechanism of Sanhan Huashi Granules on pneumonia induced by human coronavirus 229E and OC43 in mice

扫码查看
目的 考察散寒化湿颗粒对人冠状病毒229E毒株和OC43毒株感染小鼠致肺炎模型的作用机制.方法 根据不同毒株将实验分批进行,每批实验动物按体重随机分成7组:正常组、病毒感染组、磷酸氯喹片组、连花清瘟颗粒组、散寒化湿颗粒(给药组)3个剂量组,高剂量为11 g·kg-1·d-1(相当于生药52.8 g·kg-1·d-1)、中剂量为5.5 g·kg-1·d-1(相当于生药26.4 g·kg-1·d-1)、低剂量为2.75 g·kg-1·d-1(相当于生药13.2 g·kg-1·d-1).使用人冠状病毒229E和OC43感染小鼠,建立肺炎模型.通过检测肺指数和肺部病理变化等指标评价散寒化湿颗粒对冠状病毒肺炎小鼠的药理作用.结果 散寒化湿颗粒在高、中、低 3个剂量组均能有效降低小鼠的肺指数,并减轻肺组织的病理损伤.结论 散寒化湿颗粒对人冠状病毒229E毒株和OC43感染致小鼠肺炎均具有治疗作用.
Objective To investigate the pharmacological effects of Sanhan Huashi Granules on mouse pneumonia caused by human coronavirus 229E or OC43,and to provide guidance for clinical application.Methods The experiment was divided into 2 batches,and each batch of experimental animals were randomly divided into 7 groups according to body weight:normal group,viral infection model group,chloroquine phosphate tablets group and Lianhua Qingwen granules group,respectively.The Sanhan Huashi mice were divided into three groups:high dose group(11 g·kg-1·d-1,equivalent to 52.8 g crude drug g·kg-1·d-1),medium-dose group(5.5 g·kg-1·d-1,equivalent to 26.4 g crude drug g·kg-1·d-1)and low-dose group(2.75 g·kg-1·d-1,equivalent to 13.2 g crude drug g·kg-1·d-1).The mice model of pneumonia induced by human coronavirus 229E or OC43 was used to evaluate the pharmacological effect of Sanhan Huashi granules on mice with coronavirus pneumonia by detecting lung index and lung pathological changes.Results The high-dose,medium-dose and low-dose groups of Sanhan Huashi granules can reduce the lung index and alleviate the pathological injury of lung tissue in mice.Conclusion Sanhan huashi Granules have therapeutic effect on mice pneumonia caused by human coronavirus 229E or OC43 infection.

Sanhan Huashi GranulesHuman coronavirus 229E(HCoV-229E)human coronavirus OC43(HCoV-OC43)micepneumonialung indexpathological changes

张敬升、高双荣、庞博、刘莉娜、徐英莉、曹姗、陈梦苹、张宇、赵荣华、崔晓兰

展开 >

中国中医科学院中药研究所,北京 100700

江苏康缘药业股份有限公司 江苏 南京 222000

散寒化湿颗粒 人冠状病毒229E 人冠状病毒OC43 小鼠 肺炎 肺指数 病理变化

国家重点研发计划中国中医科学院科技创新工程

2021YFC1712903C12021A04606

2024

中国药物警戒
国家药品监督管理局药品评价中心(国家药品不良反应监测中心)

中国药物警戒

CSTPCD
影响因子:1.105
ISSN:1672-8629
年,卷(期):2024.21(1)
  • 7